Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SusmedTSE:4263 -4.30%73 EBIT per Share is 円-37.46 as of Dec. 2025. GuruFocus rates TSE:4263 with a GF Score™ of 73/100 and a GF Value™ of 円846.73 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 524 Healthcare Providers & Services companies, Susmed ranks worse than 74.43% on this metric.
Susmed's EBIT per Share for the
three
months ended in Dec. 2025 was 円0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was 円-37.46.
During the past 3 years, the average EBIT per Share Growth Rate was -4.50% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -1.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Susmed's EBIT per Share or its related term are showing as below:
TSE:4263'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -4.5 Med: 5.7 Max: 34.2
Current: -4.5
During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Susmed was 34.20% per year. The lowest was -4.50% per year. And the median was 5.70% per year.
TSE:4263's 3-Year EBIT Growth Rate is ranked worse than 74.43% of 524
companies
in the Healthcare Providers & Services industry
Industry Median: 11.95
vs TSE:4263: -4.50
Susmed's EBIT for the
three
months ended in Dec. 2025 was 円0.0 Mil.
Susmed (TSE:4263) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Susmed EBIT per Share Related Terms
Susmed EBIT per Share Historical Data
* Premium members only.
The historical data trend for Susmed's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-37.46
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Susmed (TSE:4263) has a EBIT per Share of 円-37.46 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Susmed and its competitors. According to the industry distribution chart, Susmed ranks #390 out of 524 companies in the Healthcare Providers & Services industry, placing it in the top 74.4%.
Is Susmed's EBIT per Share too high?
Susmed's current EBIT per Share is 円-37.46. Based on the distribution chart, Susmed ranks #390 out of 524 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Susmed has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Susmed's EBIT per Share compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Susmed ranks #390 out of 524 companies for EBIT per Share. This places Susmed in the lower half of its industry. The industry median EBIT per Share is 11.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 11.95, based on 524 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Susmed and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 11.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Susmed's current EBIT per Share is 円-37.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Susmed stock overvalued right now?
Based on GuruFocus' analysis, Susmed (TSE:4263) is currently considered Modestly Undervalued. The stock's GF Value™ is 円846.73, compared to a current price of 円690.00 — trading 18.5% below its estimated fair value. The current EBIT per Share is 円-37.46. Susmed's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Susmed (TSE:4263), the current EBIT per Share is 円-37.46 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Susmed (TSE:4263) Overvalued in 2026?
Based on GuruFocus' analysis, Susmed stock appears to be undervalued.
The current stock price of 円690.00 is trading 18.5% below its estimated GF Value™ of 円846.73.
GuruFocus considers Susmed to be Modestly Undervalued.
Key valuation signals for TSE:4263:
EBIT per Share: 円-37.46
GF Value™: 円846.73 vs. price of 円690.00 (18.5% below fair value)
No single metric tells the full story. See the TSE:4263 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Susmed Inc is engaged in the development of therapeutic smartphone apps and digital solutions to streamline clinical trials. It is currently developing therapeutic apps for patients with insomnia, breast cancer, kidney disease, and other conditions. In addition, it has developed Susumed System, which uses a proprietary blockchain technology to ensure the reliability of clinical trial data, and can reduce the manpower and costs allocated to clinical trials. The company's reportable segments are: the DTx Product Business, which derives maximum revenue, and consists of the development of therapeutic apps; and the DTx Platform Business, which provides general-purpose clinical trial systems and machine learning automated analysis systems.
73GF Score
Get the complete analysis for TSE:4263
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4263 has been successfully added to your 
